CVRx, Inc. CVRX
CVRx, Inc. (Nasdaq: CVRX) is a cardio-renal-metabolic medical device company. Its next catalyst on record is BENEFIT-HF: Landmark heart failure study evaluating Barostim in significantly expanded patient population (date not stated).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: BENEFIT-HF — Landmark heart failure study evaluating Barostim in significantly expanded patient population (date not stated). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Barostim | Heart failure with reduced ejection fraction (HFrEF) | device-combination | NA_NON_THERAPEUTIC |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.